The Economic Value of Pathology: Achieving Better Health, and a Better Use of Health Resources
On Tuesday April 12, Pathology Awareness Australia launched an exciting new report at a pathology laboratory in central Sydney as part of our ongoing work to build understanding of pathology in the community.
Written by the Centre for International Economics, it is the first report in Australia to take a detailed look at the financial savings and broad benefits that pathology provides to the health system and patients. Focusing on the examples of diabetes, heart disease and bowel cancer, it highlights the central role of pathology in the prevention, diagnosis and treatment of disease.
To find out more about the report's findings and to read it in full click here
IVD Australia Networking Event, Brisbane, 12 September 2016
Funding Advances in Diagnostic Healthcare
Brisbane Convention & Exhibition Centre
What is in Our Future
Technological advances and automation have made tests easier to use, more accurate, and have led to more precise and more timely reporting of results. These advances have led to more rapid diagnostic decision-making by medical practitioners. But, there are more, fundamental changes waiting to happen in our healthcare. These include:
- Point of Care testing providing rapid, on-the-spot answers
- Self-testing empowering patients to self-manage their condition
- Evidence-based care integrating individual clinical expertise with the best available external clinical evidence from systematic research
- Consumer devices and informatics combining monitoring and awareness
- Medical Homes to deal with chronic diseases
- Genetics and Genomics to predict and enable better intervention and health planning
- Informatics that will drive better healthcare decisions and support through a connected patient eHR
None of the above are about automation, workforce issues, management or operations; they are all about innovation.
Many of these other advances have been made possible by discoveries utilising the human genome, and have opened the door to personalised medicine approaches that can tailor medical treatment to individual patient needs, transforming modern medicine.
For our sector, the key question now is…
How will Australia fund these advances in diagnostic healthcare?
This IVD Australia event is Free for Members to attend; cost for non-members $350
Following the IVD Australia Event, any Members not already attending the AACB/AIMS Cocktail Function are invited to attend, the cost is $60pp.
Date: 16 November 2016
Venue: Aerial UTS Function Room Sydney
Registrations Open: 20 July 2016
Cost: Early Bird (to 10/10/16): $480 Non-Member; $400 Member**
Post Early Bird: $620 Non-Member; $495 Member**
$5,500 incl. GST
x 4 options
$2,750 incl. GST
x 6 Options
** Member discounts only apply to AIMS/AACB/IVD Australia Members. If you need help with registration, please contact the AIMS national office during business hours (8:30 am – 4:00pm) on (07) 3876 2988 or via email
13-15 September 2016
Brisbane Convention & Exhibition Centre, Brisbane QL
THE REIMBURSEMENT LANDSCAPE IN AUSTRALIA: THE REVIEW AND REFORM AGENDA
- The IVD Australia CEO is participating in this plenary session on Health Economics
- Date:August 10, 2016
- Time 3:30pm
Go to our Members Home Page
IVD Australia is driven by our strategic plan and we have captured two key strategies that will help to ‘future-proof’ the IVD Industry in Australia – Driving Industry Value, and Recognition & Advocacy.
All our activities are focused on member-value; ensuring that government understands, and acts upon, the value of the Australian IVD Industry; and making sure industry’s voice is heard and respected.
Read the latest IVD Australia Media Release
IVD Australia often receives requests for assistance or sourcing products from industry. Members can click here to see these opportunities (log in required).
IVD Australia Open Consultations
- Standards Australia - Oral Fluids Testing, Vendor Credentialling, Biological Evaluation
- IVD Australia - Vendor Credentialing
Visit the Open Consultations Page for more information.
Visit the Submissions Page to view our recent submissions.
IVD Transition - Update
On 30 June 2015 the transition period for all commercial IVD medical devices ceased.
Sponsors are reminded that previous Listings or Registrations representing the transitioned IVD should be removed from the ARTG. Further information can be found on the TGA website.
TGA has also confirmed that commercial sponsors of IVDs will not be required to pay annual charges until October 2017. This will provide a significant benefit for the sector, saving an estimated $5-6 million in annual charges over the next 3 years.